Incidence, cost, and outcomes of bleeding and chemotherapy dose modification among solid tumor patients with chemotherapy-induced thrombocytopenia.
about
Thrombopoietin receptor agonists for prevention and treatment of chemotherapy-induced thrombocytopenia in patients with solid tumoursIncreased risk of high-grade hemorrhage in cancer patients treated with gemcitabine: a meta-analysis of 20 randomized controlled trialsThe Effect of Ginger (Zingiber officinale) on Platelet Aggregation: A Systematic Literature ReviewManagement of CAD in Patients with Active Cancer: the Interventional Cardiologists' PerspectiveControl of bleeding caused by thrombocytopenia associated with hematologic malignancy: an audit of the clinical use of recombinant activated factor VII.Innate immune cells induce hemorrhage in tumors during thrombocytopenia.Incidence and risk factors of clinically significant chemotherapy-induced thrombocytopenia in patients with solid tumors.Dose escalation study of an anti-thrombocytopenic agent in patients with chemotherapy induced thrombocytopenia.'Pseudo Wine Glass' Radiological Appearance of Intracranial Haemorrhage as a Result of Chemotherapy-Induced Thrombocytopenia and Red Cell Sedimentation.Thrombopoietin receptor levels in tumor cell lines and primary tumorsMulticenter, randomized study of genetically modified recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in cancer patients receiving chemotherapy.Functional hyper-IL-6 from vaccinia virus-colonized tumors triggers platelet formation and helps to alleviate toxicity of mitomycin C enhanced virus therapyAnalysis of the risk factors for myelosuppression after concurrent chemoradiotherapy for patients with advanced non-small cell lung cancer.Low or undetectable TPO receptor expression in malignant tissue and cell lines derived from breast, lung, and ovarian tumors.Inverse probability weighted estimating equations for randomized trials in transfusion medicine.Pharmacokinetic/Pharmacodynamic modeling of abexinostat-induced thrombocytopenia across different patient populations: application for the determination of the maximum tolerated doses in both lymphoma and solid tumour patients.Antineoplastic agents and the associated myelosuppressive effects: a review.Evaluation of the risks of chemotherapy in dogs with thrombocytopenia.Fat composition changes in bone marrow during chemotherapy and radiation therapy.Does neoadjuvant therapy for esophageal cancer increase postoperative morbidity or mortality?Positive effects on hematological and biochemical imbalances in patients with metastatic breast cancer stage IV, of BP-C1, a new anticancer substancePlatelet factor 4 platelet levels are inversely correlated with steady-state platelet counts and with platelet transfusion needs in pediatric leukemia patients.SCAI Expert consensus statement: Evaluation, management, and special considerations of cardio-oncology patients in the cardiac catheterization laboratory (endorsed by the cardiological society of india, and sociedad Latino Americana de Cardiologıa iGenetic engineering of platelets to neutralize circulating tumor cellsMechanistic studies on the effects of nicotinamide on megakaryocytic polyploidization and the roles of NAD+ levels and SIRT inhibition.Thrombopoietin receptor agonists for prevention and treatment of chemotherapy-induced thrombocytopenia in patients with solid tumours.Comparison Between Thromboelastography and Conventional Coagulation Tests in Surgical Patients With Localized Prostate Cancer.Eltrombopag for thrombocytopenia in patients with advanced solid tumors receiving gemcitabine-based chemotherapy: a randomized, placebo-controlled phase 2 study.Interventional Cardio-Oncology: Adding a New Dimension to the Cardio-Oncology Field.Genetic polymorphism of SLC31A1 is associated with clinical outcomes of platinum-based chemotherapy in non-small-cell lung cancer patients through modulating microRNA-mediated regulation.Antithrombotic therapy for prophylaxis and treatment of venous thromboembolism in patients with cancer: review of the literature on current practice and emerging options.
P2860
Q24186714-496BF2BE-4588-4998-B8E5-C2231B0CB4B3Q28533753-D90E498E-2A78-419B-B28D-8B377871C836Q28550429-3748F62B-85D5-4CF1-AFF2-943C25D311C1Q29994512-F1E542CB-BD27-47A5-8EFD-15C877AF2DD0Q33369021-994FD6F2-D2CF-4D69-ADAB-A9CA6212829EQ33386103-50E6501D-0E38-4B8A-AA37-57AB6A154321Q33391777-3E4E6042-7C14-4BAE-933D-D2B6B320AC43Q33392349-B036A2D1-363A-4499-A602-FAA758CB9527Q33393011-D1E8E80E-D07C-484A-B97F-3DBA7F62AA34Q33394117-0DB49254-C7BD-4957-8C6E-3065762B296EQ33397918-F2C36C88-1BF2-4E65-B53D-641B9CAF41A5Q33399140-4D3FD6FE-A4F5-4487-B847-6265573FBBBDQ33403054-522EAAD6-9531-4FFE-9960-5D3FF3446130Q33403234-0345C386-27C1-43C0-948C-AE55B8E959BCQ33407359-42DEED57-1B5C-444B-9DF9-F0F712201C60Q33415594-6C8E706C-187C-48AE-ABF0-23CD063E8D45Q33417225-4E97E234-22FE-4DF8-9D6D-80B33F8E473FQ33421905-3F6D276E-BA21-4DCB-A506-5164C2758FD1Q34156572-D521E3EE-1D28-4825-99E7-F381538221ACQ35072610-9D93EB3E-77DD-4A7B-A1EC-7249991275A4Q35191247-EF2E0FB9-A414-44B9-9910-2F5B847EB508Q36075713-AD510C0C-0DE7-4101-99E9-3AF5DC76E7B7Q38693165-78C2D308-C0A1-4E7F-B044-8A04B8AC2412Q38790593-54040268-14B2-4852-B053-78E306E8F557Q42008823-3AC76509-FA18-498F-8495-7A24EC797E5BQ47409875-79D38D2A-BFF5-4FDE-9A3A-29FEA5F77CA1Q48595710-D317C533-F25E-4B3D-B26C-BB0329CCCF9AQ50231149-1F21F2CA-98F3-4E7D-AE8A-971EB2F48CADQ54941852-41F41B54-DCEC-47E2-9E7F-5DE6D362D746Q55007009-0049E306-59CA-4240-AA61-9DCAB9EF9E52Q55364590-F5C94E92-0DE9-4E0F-A0FD-B102173598CC
P2860
Incidence, cost, and outcomes of bleeding and chemotherapy dose modification among solid tumor patients with chemotherapy-induced thrombocytopenia.
description
2001 nî lūn-bûn
@nan
2001 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Incidence, cost, and outcomes ...... rapy-induced thrombocytopenia.
@ast
Incidence, cost, and outcomes ...... rapy-induced thrombocytopenia.
@en
type
label
Incidence, cost, and outcomes ...... rapy-induced thrombocytopenia.
@ast
Incidence, cost, and outcomes ...... rapy-induced thrombocytopenia.
@en
prefLabel
Incidence, cost, and outcomes ...... rapy-induced thrombocytopenia.
@ast
Incidence, cost, and outcomes ...... rapy-induced thrombocytopenia.
@en
P2093
P1476
Incidence, cost, and outcomes ...... rapy-induced thrombocytopenia.
@en
P2093
C G Martin
E B Rubenstein
L S Elting
R S Benjamin
S B Cantor
S Rodriguez
P304
P356
10.1200/JCO.2001.19.4.1137
P407
P577
2001-02-01T00:00:00Z